Real World Practice With Academic Anti CD19 CAR-T Cell Therapy in Relapse/Refractory B-cell Lymphoma

Plain-language summary

This study looks at the real-world use of an academically produced anti-CD19 CAR-T cell therapy in people with relapsed or treatment-resistant B-cell lymphoma. Adults aged 18 and over with confirmed CD19 expression in their tumor tissue who have received at least one prior line of treatment may take part. It is a study without a phase and is currently recruiting participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Recruiting

Sponsor

N.N. Alexandrov National Cancer Centre

Intervention

CAR-T cell therapy

Start date

6/1/2021

Estimated completion

1/1/2029

Countries

Belarus

Related genes

Locations

• Lyasny, Belarus

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* age ≥18 years,
* relapsed or refractory LBCL,
* confirmed CD19 expression in tumor tissue,
* prior exposure to at least one line of anti-tumor therapy

Exclusion Criteria:

* pregnancy,
* active hepatitis B or C infection, HIV infection,
* naïve T-lymphocyte count (CD3+CCR7+CD45RO-) ≤ 0,5%